PVAC Advances mRNA Vaccine Technology Transfer to Boost Local Vaccine Production in Nigeria

The Presidential Initiative on Unlocking the Healthcare Value Chain (PVAC) is facilitating the transfer of messenger RNA (mRNA) vaccine technology to Nigerian institutions and manufacturers as part of efforts to strengthen domestic vaccine production and reduce dependence on imported medical products.

The initiative is aimed at improving Nigeria’s capacity to develop and manufacture vaccines locally, strengthening the healthcare value chain, and expanding the country’s preparedness for future public health emergencies.

The transfer of mRNA technology could create opportunities for Nigerian research institutions, pharmaceutical manufacturers, and biotechnology professionals to develop expertise in advanced vaccine production. However, the successful implementation of the initiative will depend on sustained investment, technical training, adequate infrastructure, regulatory oversight, and collaboration between government agencies, researchers, and private-sector manufacturers.

mRNA technology gained international prominence during the COVID-19 pandemic, when it was used to develop vaccines at unprecedented speed. The technology enables cells to produce a specific protein that triggers an immune response, helping the body recognise and fight targeted infections.

For Nigeria, developing local vaccine manufacturing capacity could strengthen health security, improve access to essential vaccines, create skilled employment opportunities, and support the growth of the domestic pharmaceutical industry.

Nevertheless, technology transfer alone does not guarantee immediate local production. Its impact will depend on the ability of participating institutions to establish suitable manufacturing facilities, meet internationally recognised quality standards, and secure the necessary regulatory approvals.

PVAC’s efforts align with broader ambitions to strengthen Nigeria’s healthcare value chain by encouraging local investment, promoting innovation, and building domestic capacity across the pharmaceutical and medical manufacturing sectors.

The progress of the programme will ultimately be measured by its ability to translate technology transfer into sustainable manufacturing capacity, reliable vaccine supplies, and improved healthcare outcomes for Nigerians.

PVAC is facilitating mRNA vaccine technology transfer to Nigerian institutions and manufacturers to strengthen local vaccine production and improve health security.